Jump to content

mRNA-1283

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Dilettante (talk | contribs) at 21:36, 10 November 2022 (Updated). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

mRNA-1283
Vaccine description
TargetSARS-CoV-2
Vaccine typemRNA
Clinical data
Trade namesSpikevax[1]
Routes of
administration
Intramuscular

mRNA-1283 is a COVID-19 vaccine candidate developed by Moderna.[2][3]

An expectation, or hope seems to be that this "next generation" vaccine can be stored at regular refrigerator temperature (2-5 ºC).

Clinical Trial

In December, Moderna started a clinical trial which would evaluate the vaccine's ability to provoke an immune response and its safety. As of September 2022, the trial is in Phase 2 [4]


References

  1. ^ "Moderna Announces Significant Advances Across Industry-Leading mRNA Portfolio at 2021 R&D Day". Bloomberg. 9 September 2021. Retrieved 29 April 2022.
  2. ^ "A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19". ClinicalTrials.gov. 24 March 2021. NCT04813796. Retrieved 17 August 2021.
  3. ^ "A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters". ClinicalTrials.gov. 30 November 2021. NCT05137236. Retrieved 30 November 2021.
  4. ^ "A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters". ClinicalTrials.org. Retrieved 29 April 2022.